Clinical Trials Directory

Trials / Completed

CompletedNCT00596037

Treatment of Adults With Growth Hormone Deficiency

A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
136 (actual)
Sponsor
LG Life Sciences · Industry
Sex
All
Age
23 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The objective of this rollover study is to evaluate the long term (1 year) safety of a new weekly administered growth hormone preparation in adults with growth hormone deficiency who were treated with the same experimental preparation in study BPLG-005. In addition, further change in efficacy endpoints of BPLG-005 by prolonged treatment will be evaluated. Additional efficacy and safety data of the experimental preparation will be obtained from the switch-over patients.

Conditions

Interventions

TypeNameDescription
DRUGGrowth hormone - LB03002

Timeline

Start date
2006-08-01
Primary completion
2008-09-01
Completion
2009-05-01
First posted
2008-01-16
Last updated
2012-10-05

Source: ClinicalTrials.gov record NCT00596037. Inclusion in this directory is not an endorsement.

Treatment of Adults With Growth Hormone Deficiency (NCT00596037) · Clinical Trials Directory